Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, we have a portfolio of commercially-available PLAC® Tests, the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

April 20, 2015

Lori Rafield, Ph.D. Appointed Permanent CEO of Diadexus

March 24, 2015

Diadexus, Inc. Announces Presentation of Results from the PLAC® Activity Test Clinical Validation Study